- Home
- CELU vs KRRO Comparison
CELU vs KRRO Comparison
Compare CELU & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELU
- KRRO
- Stock Information
- Founded
- CELU 2016
- KRRO 2014
- Country
- CELU United States
- KRRO United States
- Employees
- CELU N/A
- KRRO N/A
- Industry
- CELU Biotechnology: Pharmaceutical Preparations
- KRRO Biotechnology: Pharmaceutical Preparations
- Sector
- CELU Health Care
- KRRO Health Care
- Exchange
- CELU Nasdaq
- KRRO Nasdaq
- Market Cap
- CELU 56.9M
- KRRO 58.6M
- IPO Year
- CELU N/A
- KRRO 2019
- Fundamental
- Price
- CELU $1.96
- KRRO $5.59
- Analyst Decision
- CELU Strong Buy
- KRRO Buy
- Analyst Count
- CELU 1
- KRRO 10
- Target Price
- CELU $6.00
- KRRO $74.17
- AVG Volume (30 Days)
- CELU 69.1K
- KRRO 1.0M
- Earning Date
- CELU 11-14-2025
- KRRO 11-12-2025
- Dividend Yield
- CELU N/A
- KRRO N/A
- EPS Growth
- CELU N/A
- KRRO N/A
- EPS
- CELU N/A
- KRRO N/A
- Revenue
- CELU $40,578,000.00
- KRRO $7,371,000.00
- Revenue This Year
- CELU N/A
- KRRO $116.91
- Revenue Next Year
- CELU $76.00
- KRRO N/A
- P/E Ratio
- CELU N/A
- KRRO N/A
- Revenue Growth
- CELU N/A
- KRRO N/A
- 52 Week Low
- CELU $1.00
- KRRO $5.42
- 52 Week High
- CELU $4.35
- KRRO $56.69
- Technical
- Relative Strength Index (RSI)
- CELU 57.50
- KRRO 21.22
- Support Level
- CELU $1.62
- KRRO $5.42
- Resistance Level
- CELU $2.29
- KRRO $6.59
- Average True Range (ATR)
- CELU 0.15
- KRRO 1.20
- MACD
- CELU 0.06
- KRRO -0.82
- Stochastic Oscillator
- CELU 63.29
- KRRO 0.70
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.